Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Publication Date: 2024 Jun 01
Full Text Sources
Silverchair Information Systems (Free)
Authors
Olivia Wagemann; Haiyan Liu; Guoqiao Wang; Xinyu Shi; Tobias Bittner; Marzia A Scelsi; Martin R Farlow; David B Clifford; Charlene Supnet-Bell; Anna M Santacruz; Andrew J Aschenbrenner; Jason J Hassenstab; Tammie L S Benzinger; Brian A Gordon; Kelley A Coalier; Carlos Cruchaga; Laura Ibanez; Richard J Perrin; Chengjie Xiong; Yan Li; John C Morris; James J Lah; Sarah B Berman; Erik D Roberson; Christopher H van Dyck; Douglas Galasko; Serge Gauthier; Ging-Yuek R Hsiung; William S Brooks; Jérémie Pariente; Catherine J Mummery; Gregory S Day; John M Ringman; Patricio Chrem Mendez; Peter St George-Hyslop; Nick C Fox; Kazushi Suzuki; Hamid R Okhravi; Jasmeer Chhatwal; Johannes Levin; Mathias Jucker; John R Sims; Karen C Holdridge; Nicholas K Proctor; Roy Yaari; Scott W Andersen; Michele Mancini; Jorge Llibre-Guerra; Randall J Bateman; Eric McDadeAbstract
OBJECTIVE
Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD).
Source
JAMA neurology
Pub Types(s)
Journal Article
Language
English
PubMed ID
38683602